[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thrombosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thrombosis":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,43,0,25,[9,50,78,111,135,158,196,232,258,288,314,337,365,399,421,442,469,492,517,547,570,601,611,650,682],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100054158","athn-transcends-a-natural-history-study-of-non-neoplastic-hematologic-disorders-100054158",false,"NCT04398628","ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders","ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders","Participants who meet the following inclusion criteria and none of the exclusion criteria are eligible for enrollment in one of the open disease-specific arms.\n\nInclusion Criteria:\n\n1. Any age\n2. Having a congenital or acquired blood disorder; or\n3. Having a bleeding phenotype as indicated by an age adjusted abnormal ISTH Bleeding Assessment Tool score with an unknown diagnosis; or\n4. Connective tissue disorder with bleeding tendency as indicated by an age adjusted abnormal ISTH Bleeding Assessment Tool score.\n5. Eligible for a currently active disease-specific arm.\n6. Concurrent enrollment in the ATHNdataset or current ATHNdataset participant.\n\nExclusion Criteria:\n\n1\\. Does not qualify for inclusion in a currently activedisease-specific arm; participants may be eligible to enroll as future cohorts and arms are activated; 2. Unable to give informed consent or assent 3. Unwilling to perform study procedures\n\nCohort Participant Selection\n\nEach participant is to be enrolled in the cohort for which they qualify as defined below.\n\nHemophilia Cohort\n\nInclusion Criteria:\n\nParticipants who meet any of the following inclusion criteria are eligible for enrollment into this cohort:\n\n1. Factor VIII or factor IX activity \\\u003C50%, without another explanation for low clotting factor other than congenital hemophilia or being a known carrier for congenital hemophilia; OR\n2. Carrier for congenital hemophilia with a factor VIII \\>=50% or factor IX activity \\>=50% with or without a bleeding phenotype as indicated by an ISTH Bleeding Assessment Tool score of ≥4 for adult males, ≥6 for adult females, or ≥3 for children younger than 18 years OR\n3. Known congenital hemophilia that have a factor level \\>50% after receiving vector, OR 4. Acquired hemophilia.\n\nExclusion Criteria:\n\nNone\n\nVon Willebrand Disease Cohort\n\nInclusion Criteria:\n\nParticipants who meet the following inclusion criteria are eligible for enrollment into this cohort:\n\n1\\. Meeting the definition of VWD or low VWF per most recent international guidelines\n\nExclusion Criteria:\n\nNone\n\nCongenital Platelet Disorders Cohort\n\nInclusion Criteria:\n\nParticipants who meet the following inclusion criteria are eligible for enrollment into this cohort:\n\n1. Abnormalities of platelet function a. Glanzmann thrombasthenia (GPIIb or GPIIIa) b. Bernard-Soulier syndrome (GPIbalpha, GPIbbeta, or GPIX)\n2. Abnormalities of platelet granules\n3. Abnormalities of platelet signal transduction\n4. Abnormalities of platelet secretion\n5. Collagen Receptor Defect\n6. ADP Receptor Defect\n7. Thromboxane Receptor Defect\n8. Giant Platelet Disorder\n9. Abnormalities in platelet aggregation testing due to another or unknown cause (not drug related)\n\nExclusion Criteria:\n\n1\\. Platelet disorders secondary to medications or other substances\n\nRare Disorders Cohort\n\nInclusion Criteria:\n\nParticipants who meet the following inclusion criteria are eligible for enrollment into this cohort:\n\n1\\. Have an established Rare Coagulation Disorder (RCD) diagnosis of one of the following:\n\n1. PAI-1 deficiency\n2. Factor I, II, V, VII, X, XI, XIII deficiencies\n3. Combined FV and FVIII deficiency\n4. Plasminogen deficiency\n5. Decreased tissue plasminogen activator\n6. Afibrinogenemia\u002Fhypofibrinogenemia\u002Fdysfibrinogenemia\n7. Thrombotic Thrombocytopenia Purpura or Congenital Hemolytic Uremic Syndrome\n8. Wiskott-Aldrich\n9. Methylenetetrahydrofolate Reductase Deficiency\n\nExclusion Criteria:\n\nNone\n\nBleeding NOS Cohort\n\nInclusion Criteria:\n\nParticipants who meet the following inclusion criteria are eligible for enrollment into this cohort:\n\n1. Have a bleeding phenotype as indicated by an ISTH Bleeding Assessment Tool score of ≥4 for adult males, ≥6 for adult females, or ≥3 for children younger than 18 years with an unknown diagnosis, OR\n2. Connective tissue disorder with bleeding tendency as indicated by an ISTH Bleeding Assessment Tool score of ≥4 for adult males, ≥6 for adult females, or ≥3 for children younger than 18 years.\n\nExclusion Criteria:\n\nNone\n\nThrombosis\u002FThrombophilia Cohort\n\nInclusion Criteria\n\nParticipants who meet the following inclusion criteria are eligible for enrollment into this cohort:\n\n1\\. Have a prior history of arterial or venous thrombosis. 2. Participants with a known congenital or acquired thrombophilia with or without thrombosis.\n\na. Common congenital thrombophilias: i. Protein C deficiency ii. Protein S deficiency iii. Antithrombin deficiency iv. Factor V Leiden v. Prothrombin gene mutation b. Rare genetic factors i. Hyperhomocysteinemia c. Indeterminate genetic factors i. Elevated factor VIII ii. Elevated factor IX iii. Elevated factor XI iv. Elevated lipoprotein (a) d. Acquired thrombophilias i. Lupus anticoagulant ii. Anti-cardiolipin antibodies\u002FBeta2 glycoprotein antibodies iii. Antiphospholipid syndrome\n\nExclusion Criteria Acquired thrombophilia secondary to medications (birth control pills or hormone replacement therapy), overweight or obesity, smoking, cancer, pregnancy, surgery, injury, prolonged inactivity\u002Fbedrest, heart failure, inflammatory bowel disease, or kidney disease\n\nNon-Neoplastic Hematologic Conditions Cohort\n\nInclusion Criteria\n\nParticipants who meet the following inclusion criteria are eligible for enrollment into this cohort:\n\n1\\. Having any congenital or acquired non-neoplastic hematologic disorder not included in any other cohort\n\nExclusion Criteria None\n\nArm\u002FModule Participant Selection\n\nPreviously Untreated Patients Arm\n\nInclusion Criteria:\n\n1. Diagnosis of congenital hemophilia A (FVIII \\\u003C40%) or hemophilia B (FIX \\\u003C40% or below lower limit for age)\n2. Age \\\u003C18 years at time of enrollment\n3. Parent or authorized guardian or legally authorized representative (LAR) can provide informed consent\n4. Care established at one of the ATHN Transcends participating HTCs\n5. Clotting Factor Concentrate (CFC) exposure, fresh frozen plasma (FFP), cryoprecipitate, and single donor platelets \\\u003C3 exposure days (ED)\n\nExclusion Criteria\n\n1. Concomitant diagnosis with another bleeding disorder\n2. History of a confirmed, positive inhibitor\n\nINHIBIT Module\n\nInclusion Criteria:\n\n1\\. Diagnosis of severe factor VIII deficiency with baseline factor VIII level \\\u003C1% 2. Initiating or plan to initiate prophylaxis with emicizumab or factor replacement 3. Factor concentrate exposure, Fresh Frozen Plasma (FFP), cryoprecipitate, and single donor platelets ≤3 EDs 4. ≤5 years of age\n\nExclusion Criteria\n\n1. Concomitant diagnosis with bleeding disorder other than hemophilia A\n2. Immune disorder\n3. Previous history or presence of factor VIII inhibitor. A confirmed, positive inhibitor is defined as two consecutive positive inhibitor titers (≥ 0.6 BU) that result in changes in treatment recommendations.\n\nEfanesoctocog alfa (ALTUVIIIO®) Module\n\nInclusion criteria:\n\n1. Ability of the potential participant's legally authorized representative (e.g., their parent or legal guardian) to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local participant privacy regulation.\n2. People with severe HA with a baseline FVIII activity of less than 1%. (While inclusion for participation in ATHN Transcends lists \\\u003C5% FVIII activity, this proposed module will limit enrollment to people with FVIII activity levels of \\\u003C1%.) Other severities may be included per ATHN Transcends PI approval.\n3. \\\u003C18 years of age.\n4. No history of a confirmed, positive FVIII inhibitor.\n5. Sex assigned at birth of male, female, or intersex.\n6. Participants should have no more than three (3) exposure days of blood products (fresh frozen plasma, cryoprecipitate, or platelets), no more than three (3) doses of any FVIII concentrate other than efanesoctocog alfa, and up to three (3) doses of efanesoctocog alfa prior to enrollment.\n7. Site PI confirmed all inclusion criteria has been met.\n\nExclusion criteria:\n\n1. Not meeting all the inclusion criteria; confirmed by site PI.\n2. Any exposure to blood products or FVIII replacement products except as described in the inclusion criteria.\n3. History of positive inhibitor testing.\n4. History of hypersensitivity reactions associated with efanesoctocog alfa administration.\n5. Other coagulation disorder(s) in addition to Hemophilia A.\n6. Any concurrent clinically significant major disease such as cancer that, in the opinion of the investigator, would make the participant unsuitable for enrollment.\n7. Concurrent systemic treatment with chemotherapy and\u002For other immunosuppressant medications. Use of corticosteroids for the treatment of asthma or management of acute allergic or otherwise life-threatening episodes is allowed except for systemic corticosteroid treatment given to children daily or on an alternate day schedule at \\> 2 mg\u002Fkg\u002Fday of prednisone or its equivalent or \\> 20 mg\u002Fday if the duration is longer than 14 days.\n8. Enrollment in a concurrent clinical interventional drug study.\n9. Intake of an Investigational Medicinal Product within three (3) months prior to inclusion in this study.\n10. Inability to comply with study requirements.\n11. Other, unspecified reasons that, in the investigator's opinion, make the participant unsuitable for enrollment.\n\nHemophilia Natural History Arm\n\nInclusion Criteria\n\n1. Congenital or acquired hemophilia A or B of any severity with or without inhibitors receiving a current therapy, a non-factor product, or for whom use of a non-factor product is a possibility, OR\n2. Females of any age, with confirmed congenital hemophilia A or B carrier status with genetic mutational analysis and any factor level.\n\nExclusion Criteria\n\n1. Presence of any known bleeding disorder other than congenital hemophilia A or B\n2. Presence of concurrent hemophilia and a second hemostatic defect (low von Willebrand Factor (vWF) without vWD diagnosis is not excluded)\n3. Unable or unwilling to comply with the study arm protocol.\n\nNonacog beta pegol (Rebinyn®) Module\n\nInclusion Criteria:\n\n1. Has provided signed written consent for the nonacog beta pegol (Rebinyn®)Module before any study-related activities.\n2. Male participants, at any age with hemophilia B, naïve or minimally exposed (up to 3 EDs) to nonacog beta pegol treatment at time of study enrollment. Additional doses may be allowable per ATHN Transcends PI approval.\n3. Decision to initiate continuous prophylaxis treatment with commercially available nonacog beta pegol has been made by the participant(s)\u002FLegally Authorized Representative(s) (LAR(s)) and the treating physician before and independently from the decision to include the participant in this study.\n\nExclusion Criteria:\n\n1. Previous participation in this study. Participation is defined as having given informed consent in this study.\n2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation, including a diagnosis or suspicion of attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) per the discretion of the Principal Investigator.\n3. Known or suspected hypersensitivity to nonacog beta pegol or related products.\n4. Clinical suspicion or presence of FIX inhibitor at time of inclusion.\n5. Inability or unwillingness to undergo neurological assessment\u002Fstructured developmental history.\n\nEmicizumab (Hemlibra®) Module\n\nInclusion Criteria:\n\n1. Participant currently treated with emicizumab (Hemlibra®)\n2. Currently enrolled in the Hemophilia Natural History Arm of ATHN Transcends\n\nExclusion Criteria:\n\n1\\. Unable or unwilling to comply with the protocol\n\nDistress Module\n\nInclusion Criteria:\n\n1. Congenital hemophilia A or B of any severity with or without inhibitors receiving a current therapy, a non-factor product, or for whom use of a non-factor product is a possibility\n2. Age 18 years of age or older\n3. English speaking\n\nExclusion Criteria:\n\n1. Presence of any known bleeding disorder other than congenital hemophilia A or B;\n2. Presence of concurrent hemophilia and a second hemostatic defect (low von Willebrand Factor (vWF) without vWD diagnosis is not excluded); and\n3. Unable or unwilling to comply with the study arm protocol\n\nHemophilia Gene Therapy Outcomes Arm\n\nInclusion Criteria\n\n1. Hemophilia A or B of any severity with or without inhibitors having received or will receive a hemophilia gene transfer product in the next 6 months.\n2. Age 18 years and older.\n3. Able to give informed consent.\n\nExclusion Criteria None\n\nEtranacogene dezaparvovec (HEMGENIX®) Module\n\nInclusion Criteria:\n\nEtranacogene dezaparvovec (HEMGENIX®) Cohort\n\n1. Age 18 years of age or older\n2. Treatment with commercial etranacogene dezaparvovec (HEMGENIX®)\n3. Have provided signed written informed consent within 3 months before or within 6 months after etranacogene dezaparvovec (HEMGENIX®) treatment, or within 6 months of when the study is initiated at the treating site.\n\nFIX Prophylaxis Cohort\n\n1. Age 18 years of age or older\n2. Treatment with FIX prophylaxis therapy\n3. Has provided signed written consent at any time for ATHN Transcends Study\n\nExclusion Criteria, both cohorts:\n\n1\\. Have been treated with etranacogene dezaparvovec in a clinical trial prior to commercial availability. These patients are still eligible for enrollment in the Gene Therapy Outcomes Arm, and their data may be collected for separate analysis.\n\nCongenital Platelet Disorders Arm\n\nInclusion Criteria\n\n1. Platelet adhesion defect\n\n   1. Bernard Soulier syndrome (Defective GPIb-IX-V receptor, impaired adhesion to vWF)\n   2. Velocardio-facial syndrome\u002FDiGeorge syndrome (Defective GPIb-IX-V receptor)\n   3. Platelet type vWD (Defective GPIb-IX-V, gain of function interaction between vWF-GP1bα)\n2. Platelet aggregation defect\n\n   1. Glanzmann thrombasthenia (Defective integrin αIIbβ3 (GPIIb\u002FIIIa)\n   2. Platelet aggregation defect, NOS\n3. Agonist receptor defects\n\n   1. Epinephrine\n   2. ADP\n   3. Collagen\n   4. Thromboxane A2\n4. Platelet signaling defects\n\n   1. Cyclooxygenase deficiency (PTGS1 mutation)\n   2. Phospholipase A2 deficiency\n   3. Thromboxane synthase deficiency (TBXAS1 mutation)\n   4. G protein activation defect (GNAS mutation)\n   5. Scott syndrome (defect in phosphatidyl serine translocation)\n5. Platelet Granule disorders\n\n   1. Dense granule storage pool disorder\n\n      * Hermansky Pudlak syndrome\n      * Chediak Higashi syndrome\n      * Griscelli syndrome\n   2. Alpha granule storage pool disorder\n\n      * Grey platelet syndrome\n      * Arthrogryposis-Renal Dysfunction-Cholestasis (ARC) syndrome\n      * Quebec platelet disorder\n      * Paris-Trousseau syndrome\n   3. Combined alpha delta granule deficiency\n6. Platelet cytoskeletal structure defects\n\n   1. Wiskott Aldrich syndrome\n   2. MYH9 associated disorders (myosin heavy chain)\n\n      * May Hegglin syndrome\n      * Fechtner syndrome\n      * Sebastian syndrome\n      * Epstein syndrome\n   3. Other mutations\n\n      * FLNA mutations (Filamin)\n      * DIAPH1 (Actin and microtubules)\n      * ACTN1 (alpha actinin)\n      * TPM4 (tropomyosin)\n      * TUBB1 (beta tubulin)\n7. Other Congenital thrombocytopenias\n\n   1. Familial platelet disorders and predisposition to AML (RUNX1)\n   2. X linked thrombocytopenia with dyserythropoiesis (GATA1)\n   3. Congenital amegakaryocytic thrombocytopenia (MPL)\n\nExclusion Criteria\n\n1. Diagnosis of von Willebrand Disease (Meeting the definition of vWD or low vWF per most recent international guidelines)\n2. Diagnosis of Hemophilia A or Hemophilia B (Factor VIII or IX ≤ 40%)\n\nGlanzmann Thrombasthenia (GT) Module\n\nInclusion Criteria\n\n1. Participant has signed the informed consent\u002Fassent form\n2. Participant has flow cytometry or aggregometry or genetics confirmed GT\n3. Participant is willing to perform study procedures, including daily bleed tracking for 3 months and further if requested\n4. Participants are 2 years or older at time of consent\n\nExclusion Criteria None","ALL",{"count":19,"type":20},3000,"ESTIMATED","OBSERVATIONAL","In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.2,3,4,5\n\nIn 2019 alone, the FDA has issued approvals for 24 new therapies for congenital and acquired hematologic conditions.6 In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.7\n\nWith this increase in potential new therapies possible, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.8",[24,25,26,27,28,29,30,31,32,33,34,35,36],"Hematologic Disorder","Bleeding Disorder","Connective Tissue Disorder","Hemophilia","Thrombosis","Von Willebrand Diseases","Thrombophilia","Rare Bleeding Disorder","Platelet Disorder","Factor IX Deficiency","Factor VIII Deficiency","Thalassemia","Sickle Cell Disease","RECRUITING","2026-07-10",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":41},"2020-09-30",{"date":45,"type":20},"2035-12",{"name":47,"class":48},"American Thrombosis and Hemostasis Network","NETWORK",71,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100544545","phase-3-thromboprophylaxis-in-lower-limb-immobilisation-100544545","NCT06370273","Thromboprophylaxis in Lower Limb Immobilisation","Thromboprophylaxis in Lower Limb Immobilisation (TiLLI): a Multicentre Study Comprising Two Linked Open Label Phase III Randomised Controlled Trials Evaluating the Effectiveness and Cost Effectiveness of Different Methods of Pharmacological Prophylaxis for Patients With Temporary Lower Limb Immobilisation.","TiLLI","Inclusion Criteria:\n\n* Age \\>\u002F= 16 years\n* Placed in temporary lower limb immobilisation (rigid cast or brace) as a result an injury that occurred within the last 7 calendar days\n\nExclusion Criteria:\n\n* Hospital admission is required direct from the emergency department, minor injuries unit, or fracture clinic setting with an expected length of stay \\>2 calendar days.\n* Absolute contraindication or known hypersensitivity to anticoagulants, including history of end stage renal failure (eGFR \\\u003C20ml\u002Fmin\u002F1.73m2), hepatic failure or use of concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole), HIV protease inhibitors (e.g. ritonavir) or active substances strongly inhibiting elimination pathways such as CYP3A4 or P-gp (such as clarithromycin, erythromycin or dronaderone) or a history of heparin induced thrombocytopenia.\n* Pregnancy, actively seeking conception, or active breastfeeding.\n* Preceding use of anticoagulant treatment for \\>3 calendar days at prophylactic or therapeutic dose.\n* Prior enrolment in the TiLLI study.\n* Non-rigid immobilisation (crepe bandage, tubigrip support, strapping).\n* Time since prescription of rigid immobilisation \\>3 calendar days\n* Co-enrolment onto a CTIMP where an anticoagulant is administered\n* People lacking the capacity to consent\n* Inability or refusal to use acceptable contraception up until after the last administration of IMP. Only applicable for women of childbearing potential who have been randomised to receive apixaban or rivaroxaban","16 Years",{"count":60,"type":20},10044,"INTERVENTIONAL",[63],"PHASE3","The goal of this clinical trial is to find out the clinical and cost effectiveness of Thromboprophylaxis in participants who have been placed in a plaster cast or splint after injury.\n\nThe main questions it aims to answer are:\n\n* whether giving tablets to people at high risks of clots after a leg injury is as good as injections (standard care)\n* whether giving any medication after a leg injury is better than standard care (advice only) for people at low risk of clots.\n\nParticipants will be assessed to be high risk (TiLLI High) or low risk (TiLLI Low). People who are at high risk of clots will have either tablets or injections to reduce their risk. People at low risk will receive tablets, injections or no medication.\n\nDrug treatments will be provided for the duration of immobilisation or up to 42 days (whichever is earlier), in accordance with current NICE guidelines. The participants will be followed up for 90 days following randomisation.",[28,66],"Injury Leg","2026-07-01",{"date":69,"type":41},"2026-07-02",{"date":71,"type":41},"2024-11-12",{"date":73,"type":20},"2028-08-31",{"name":75,"class":76},"Queen Mary University of London","OTHER",5,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100639802","platelets-and-extracorporeal-membrane-oxygenation-veno-venous-100639802","NCT07580469","Platelets and Extracorporeal Membrane Oxygenation Veno-venous","Study of PLATelet Functions and Risk Factors for Hemorrhagic Complications in Patients on Extracorporeal Membrane Oxygenation Veno-venous: Prospective Monocentric Cohort","PLAT-VV-ECMO","Inclusion Criteria:\n\n* Adults aged ≥ 18 years\n* No objection to participation in the study, obtained from a relative or trusted person; if no relative is available, inclusion under emergency procedure (pending patient or relative non-opposition)\n* Patients requiring admission to the general intensive care unit of Hôpital Rangueil for venovenous ECMO\n* Equipped with an arterial catheter for blood sampling\n* Ability to undergo the 4 blood draws relevant to the study\n* Receiving therapeutic anticoagulation with unfractionated heparin\n* Enrolled in a social security program or equivalent\n* No measures for Limitation and Withdrawal of Therapy have been implemented\n\nExclusion Criteria:\n\n* Minors\n* Patients under court-appointed guardianship or conservatorship\n* Pregnant or breastfeeding women\n* Hematological disease (leukemia, lymphoma) or constitutional thrombocytopenia\n* Platelet transfusion within 7 days prior to enrollment\n* Indication for immediate emergency ECMO preventing blood sampling before placement\n* Post-cardiotomy\n* Patient on antiplatelet therapy\n* Severe thrombocytopenia \\\u003C50 G\u002FL\n* Other invasive mechanical support such as Impella®, intra-aortic balloon pump, or Left Ventricular Assist Device (LVAD)","18 Years",{"count":88,"type":20},40,"In severe lung or heart disease, ExtraCorporeal Membrane Oxygenation (ECMO) may be used temporarily and can be responsible for major haemorrhagic complications. Thrombocytopenia and possibly thrombopathy promote bleeding. The primary objective is to characterize platelet dysfunction by aggregometry tests over time. Secondarily, investigators seek a correlation between haemorrhagic complications at day 10 and markers of platelet action and dysfunction; also, with the level of anticoagulation and inflammation by biomarkers.",[91,92,93,28],"Extracorporeal Membrane Oxygenation Complication","Hemorrhage","Blood Platelet Disorder",[95,96,97,98,99],"VV-ECMO","Platelets","Thrombopathy","thrombo-haemorrhagic complications","thrombo-inflammation","NOT_YET_RECRUITING","2026-06-24",{"date":103,"type":41},"2026-06-29",{"date":105,"type":20},"2026-09",{"date":107,"type":20},"2028-12-31",{"name":109,"class":76},"University Hospital, Toulouse",1,{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100543556","association-of-anti-factor-xa-activity-with-venous-thromboembolism-in-critically-ill-patients-100543556","NCT06357403","Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients","Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients: a Prospective Multicentre Cohort Study","AntiXa-ICU","Inclusion Criteria:\n\n* Age over 18 years at the time of intensive care unit admission\n* Admission to a participating intensive care unit within the last 24 hours\n* Expected discharge is later than 48 hours after enrolment\n\nExclusion Criteria:\n\n* Therapeutic anticoagulation, defined as enoxaparin dose of at least 100 IE\u002Fkg when given twice daily or of at least 150 IE\u002Fkg when given once daily\n* Extracorporeal membrane oxygenation in place or planned within 48 hours of study enrolment\n* Planned regular administration of vitamin K antagonists, unfractionated heparin, low molecular weight heparin other than enoxaparin, thrombin inhibitors or factor X inhibitors within the observation period\n* Estimated life expectancy below 48 hours or comfort terminal care order in place\n* Previously diagnosed heparin-induced thrombocytopenia\n* Pre-operative admission for elective surgery\n* Previous enrolment in the study",{"count":120,"type":20},1300,"The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and\u002For pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are:\n\n* What is the association between antiXa and VTE?\n* What is the association between antiXa and symptomatic, respectively incidental, VTE?\n* How is pharmacological anticoagulation with enoxaparin related to measured antiXa?\n* What is the association between antiXa and bleeding complications.\n* What is the incidence of venous thromboembolism in patients treated at an intensive care unit?\n* How is the occurence of VTE related to patient-centred outcomes such as mortality, quality of life, length of stay and days outside of the intensive care unit\u002Fhospital.",[28,123,124],"Pulmonary Embolism","Enoxaparin","2026-06-18",{"date":127,"type":41},"2026-06-23",{"date":129,"type":41},"2024-05-04",{"date":131,"type":20},"2027-08",{"name":133,"class":76},"Medical University of Vienna",3,{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":142,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":143,"targetDuration":145,"studyType":21,"phases":4,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100643161","national-study-on-the-prevalence-of-catheter-related-venous-thrombosis-100643161","NCT07643246","National Study on the Prevalence of Catheter-Related Venous Thrombosis","TROMBO","Inclusion Criteria:\n\n* All hospitalized patients aged ≥18 years from all hospital wards, including critical care units, who are carriers of a midline, FICC, PICC, or CICC catheter with a dwell time of at least 7 days will be included.\n\nExclusion Criteria:\n\n* Patients who do not provide informed consent for the ultrasound assessment.",true,{"count":144,"type":20},500,"1 Day","The aim is to determine the prevalence of catheter-related thrombosis (CRT) in hospitalized patients carrying PICC, FICC, CICC, and midline catheters through a multicenter, standardized prevalence study. To achieve this, a cross-sectional study with prospective data collection will be conducted, including, through consecutive sampling to minimize selection bias, all hospitalized patients over 18 years of age from both general wards and critical care units who have had one of these catheters in place for at least 7 days. During data collection, an ultrasound examination of the catheter insertion site will be performed in order to rule out the presence of thrombotic complications.",[28,148],"Venous Catheterization","2026-06-08",{"date":151,"type":41},"2026-06-11",{"date":153,"type":20},"2026-05-25",{"date":155,"type":20},"2026-06-19",{"name":157,"class":76},"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta",{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":61,"phases":168,"briefSummary":170,"conditions":171,"keywords":183,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":4},"100642101","phase-4-study-of-aspirin-removal-in-patients-supported-by-the-fully-magnetically-levitated-ch-vad-pump-100642101","NCT07644247","STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump","A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump (STAR Trial)","STAR","Inclusion Criteria:\n\n\\-\n\nStudy participants must meet all the following criteria:\n\n1. Age ≥18 years old;\n2. Implanted with the CH-VAD pump for advanced heart failure, and the CH-VAD pump is the first implanted left ventricular assist device;\n3. Able to understand the study purpose, voluntarily participate and sign the informed consent form, and willing to comply with the study procedures and follow-up requirements.\n\nExclusion Criteria:\n\n\\-\n\nStudy participants meet any of the following criteria will be excluded:\n\n1. Requirement for additional temporary or permanent mechanical circulatory support after LVAD implantation;\n2. Requirement for physician-mandated antiplatelet therapy after implantation due to medical history, surgical history, concomitant surgical procedures, or other conditions, including mandated presence or absence of antiplatelet agent;\n3. Occurrence of primary endpoint events prior to randomization (within 2-7 days after implantation);\n4. Inability to take oral medications post-implant through 7 days;\n5. Known allergy to aspirin;\n6. Participation in another clinical investigation that may affect study outcome;\n7. Presence of other comorbid conditions, social or psychological conditions, or other conditions, in the investigator's opinion, that may affect participation in the study or compliance with follow-up requirements.",{"count":167,"type":20},370,[169],"PHASE4","This multi-center, prospective, randomized, double-blinded, placebo-controlled study aims to investigate whether withdrawal of aspirin from the antithrombotic regimen in patients supported with the CH-VAD pump is non-inferior to the standard antithrombotic regimen of vitamin K antagonist combined with aspirin in terms of safety and efficacy.",[172,173,174,175,176,28,177,178,179,180,181,182],"LVAD (Left Ventricular Assist Device) Thrombosis","LVAD","LVAD (Left Ventricular Assist Device)","LVAD-related GI Bleed","Bleeding","Stroke","Hemocompatibility-related Adverse Event","Ventricular Assist Device","Aspirin","Antiplatelet Therapy","Antithrombotic Therapy",[184,173,177,176,28,185,180,186],"Left ventricular assist device","Hemocompatibility","Antiplatelet",{"date":188,"type":41},"2026-06-12",{"date":190,"type":20},"2026-06-25",{"date":192,"type":20},"2029-12-31",{"name":194,"class":195},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":61,"phases":205,"briefSummary":207,"conditions":208,"keywords":215,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":231},"100638631","personalizing-thromboprophylaxis-for-patients-with-peripheral-artery-disease-100638631","NCT07613840","Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease","Personalizing Post Surgical Thromboprophylaxis for Patients With Peripheral Artery Disease","Inclusion Criteria:\n\n* Patients with a named arterial extremity injury or named vessel revascularization for atherosclerosis requiring open and\u002For closed revascularization.\n* Patients at the age of 18 or older\n\nExclusion Criteria:\n\n* Patients who are younger than 18 years old\n* Known pregnancy (females of childbearing potential will have a pregnancy test prior to surgery as per standard of care)\n* Prisoners, defined as those who have been directly admitted from a correctional facility.\n* No atherosclerosis\n* Subject has active stomach ulcers\n* Subject has severe hepatic impairment\n* Subject has a recent history of intracranial hemorrhage. If the patient has a history of cerebral hemorrhage with no new central nervous system disease of \\>1 year, the study team will consult with the",{"count":204,"type":20},484,[206],"NA","The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore blood flow to their legs.\n\nThe main questions it aims to answer are:\n\n* Does the personalized plan lower the rate of blood clots in the treated leg one year after the procedure?\n* Does the personalized plan lower rates of amputation, repeat procedures, bleeding, and death compared to standard treatment?\n\nResearchers will compare the personalized TARGET plan which uses a blood test to tailor each person's blood clot prevention medication to the standard treatment to see if the personalized approach works better.\n\nParticipants will:\n\n* Be randomly assigned to either the personalized TARGET plan or standard treatment after their procedure\n* Have blood tests at 1 week and at 1, 3, 6, 9, and 12 months after their procedure\n* Have medications adjusted based on blood test results if assigned to the TARGET group",[209,210,28,211,212,213,214],"Peripheral Arterial Disease (PAD)","Amputation","Thrombosis (Stent Thrombosis)","Platelet Aggregation Inhibitors","Thromboelastography (TEG)","PRU(Platelet Reactivity Unit)",[216,217,218,219,220,221],"Peripheral Artery Disease Thromboprophylaxis","Personalizing Blood Thinners","Clopidogrel Resistance","Thromboelastography with Platelet Mapping (TEG-PM)","Graft\u002F Stent Thrombosis","Platelet Inhibition","2026-05-21",{"date":224,"type":41},"2026-05-29",{"date":226,"type":41},"2025-04-29",{"date":228,"type":20},"2027-06-30",{"name":230,"class":76},"Massachusetts General Hospital",2,{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":240,"targetDuration":241,"studyType":21,"phases":4,"briefSummary":242,"conditions":243,"keywords":246,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":110},"100382658","international-registry-of-thrombotic-aps-patients-treated-with-direct-oral-anticoagulants-100382658","NCT04262492","International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants","OBServaToire INternational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs","OBSTINATE","Inclusion Criteria:\n\n* Patient receiving a comprehensive information about the study, and not opposed to participate\n* Age ≥ 18 yo\n* Classification of definite APS according to revised Sapporo-Sydney criteria\n* Direct oral anticoagulant treatment prescribed during at least 6 months or with the possibility of follow-up of at least 6 months\n\nExclusion Criteria:\n\n* Incomplete revised Sapporo-Sydney criteria\n* No data regarding the recurrent thrombosis\n* Pregnant woman\n* Age \\\u003C 18 yo",{"count":144,"type":20},"5 Years","This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.",[244,28,245],"Antiphospholipid Syndrome","Anticoagulants Causing Adverse Effects in Therapeutic Use",[247,248],"antiphospholipid syndrome","direct oral anticoagulants","2026-05-07",{"date":251,"type":41},"2026-05-08",{"date":253,"type":41},"2020-10-21",{"date":255,"type":20},"2031-04-21",{"name":257,"class":76},"Stéphane Zuily",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":267,"conditions":268,"keywords":273,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":110},"100579147","athndataset-registry-100579147","NCT06820515","ATHNdataset Registry","American Thrombosis and Hemostasis Network ATHNdataset Registry","Inclusion Criteria:\n\n* Any participant evaluated for or the potential to have a blood disorder who has an encounter with an ATHN Affiliate.\n* Participants of any age.\n* Participant is able to provide consent or assent; a Legally Authorized Representative (LAR) may provide consent on a participant's behalf if a participant is unable to provide self-consent\n\nExclusion Criteria:\n\n* Any participant unable to provide consent or assent to participate in the ATHNdataset",{"count":266,"type":20},200000,"The Hemophilia Treatment Center (HTC) where you receive care is working with The American Thrombosis and Hemostasis Network (ATHN) to look at the quality of life of people with blood disorders and problems.\n\nDoctors, scientists, policymakers, and other health care providers need a large amount of information from a lot of people to answer scientific, public health, and policy questions about better ways to treat blood disorders. They will use the information from the ATHNdataset to answer these questions.",[27,28,269,270,36,271,25,272,29],"Hemophilia A","Hemophilia B","Glanzmann Thrombasthenia","Blood Disorder",[274,275,276,277,278,279],"bleed event","bleed treatments","adverse events","joint bleed","bleeding disorder","bleeding symptoms","2026-04-16",{"date":282,"type":41},"2026-04-21",{"date":284,"type":41},"2024-10-25",{"date":286,"type":20},"2055-10-31",{"name":47,"class":48},{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":61,"phases":297,"briefSummary":298,"conditions":299,"keywords":304,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":4},"100632870","effectiveness-of-a-needle-free-connector-with-anti-reflux-technology-in-reducing-complications-from-long-peripheral-venous-catheters-in-hospitalised-adult-patients-randomised-clinical-trial-100632870","NCT07519304","Effectiveness of a Needle-free Connector With Anti-reflux Technology in Reducing Complications From Long Peripheral Venous Catheters in Hospitalised Adult Patients: Randomised Clinical Trial","FLUSH-ETI","Inclusion Criteria:\n\n* Patients requiring placement of a long peripheral venous catheter.\n* Patients who have provided written informed consent.\n* Patients with an expected hospital stay of ≥7 days.\n\nExclusion Criteria:\n\n\\- Inability to place a long peripheral venous catheter in the upper limbs.",{"count":296,"type":20},62,[206],"A study to evaluate a needle-free connector (a stopper) featuring anti-reflux technology (to prevent blood from flowing back) for catheters (polyurethane tubes inserted into a vein), with the aim of reducing complications associated with these devices: blockages, infections, pain, etc.",[300,301,302,28,303],"Vascular Access Devices","Catheters","Occlusion","Randomised Controlled Trial",[305],"Needleless connector","2026-04-15",{"date":280,"type":41},{"date":309,"type":20},"2026-04-20",{"date":311,"type":20},"2026-12-31",{"name":313,"class":76},"Hospital Arnau de Vilanova",{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":142,"sex":17,"minAge":86,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":110},"100603508","platelet-volunteers-longitudinal-and-multi-omic-study-100603508","NCT07137429","Platelet Volunteers, Longitudinal and Multi-omic Study","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures, including fasting at least 10 hours before each blood draw\n* Stated willingness to refrain from aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) for 7 days prior to any visits\n* Age \\>= 18 years\n* In good general health as evidenced by self-reported medical history\n\nEXCLUSION CRITERIA:\n\nAn individual who, by self-report, meets the following criteria will be excluded from participation in this study:\n\n* Current pregnancy or lactation\n* Active malignancies known, active known auto-immune disease, known major CVD (e.g., heart attack, stroke, venous thromboembolism, heart failure), severe bleeding history, on regular P2Y12 inhibitors or other antiplatelet treatments for a clinical reason, uncontrolled hypertension or diabetes","100 Years",{"count":322,"type":20},400,"Background:\n\nPlatelets are a type of blood cell that play a critical role in bleeding, forming blood clots, and healing. Researchers want to know more about platelets work in healthy people. They want to look at how platelets clump together, how blood clots, and how genes and proteins work. They also want to study how these processes change over time and how they are affected by factors such diet, exercise, weight, and new health problems.\n\nObjective:\n\nTo study how platelets function in healthy people.\n\nEligibility:\n\nHealthy people aged 18 years and older.\n\nDesign:\n\nResearchers will review participants medical history. They will ask about the participant s family history and any drugs they take.\n\nParticipants will have a clinic visit once every 6 or 7 months for 10 years. Each visit will be 2 to 3 hours.\n\nAt each visit, participants will have several tests and procedures:\n\nA physical exam, including vital signs. Hip and ankle circumference will be measured.\n\nUrine collection.\n\nBlood tests. About 10 tablespoons of blood will be drawn. Participants will be asked to fast for 10 hours and avoid drugs like aspirin or Advil for 7 days before each draw. Some of the blood may be used for gene studies. Some may be used to create stem cells for research. Stem cells are cells that can be used to make other types of cells.\n\nSurveys and questionnaires. Participants will answer questions about habitual activity, diet, smoking, drugs and alcohol, sleep, illness, and other health issues. These surveys may be done online, via email, or by phone.",[28],[326,327],"PLATELET FUNCTION","Platelet biology","2026-04-14",{"date":306,"type":41},{"date":331,"type":41},"2026-03-26",{"date":333,"type":20},"2041-09-15",{"name":335,"class":336},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":134},"100633222","multi-omics-based-novel-thrombosis-and-bleeding-markers-and-risk-model-for-chd-100633222","NCT07523880","Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD","Multi-Omics-Based Development of Novel Thrombosis and Bleeding Markers and Construction of a Risk Prediction Model in Coronary Heart Disease","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Hospitalized due to symptoms or objective evidence of coronary heart disease and planned for long-term antithrombotic therapy.\n3. Diagnosis of acute coronary syndrome or stable coronary heart disease undergoing percutaneous coronary intervention (PCI), with clinical stability meeting discharge criteria after treatment.\n4. For patients from the existing cohort: minimum 2 years of follow-up with complete clinical data and blood specimens available; approval for use of these data and specimens has been obtained, with a waiver of re-consent.\n\nFor newly enrolled patients: voluntary written informed consent provided by the patient or legal representative, agreement to provide blood samples, and acceptance of follow-up procedures.\n\nExclusion Criteria:\n\nFor patients from the existing cohort:\n\n1. Severe missing or erroneous baseline or clinical data that cannot be corrected by source verification.\n2. No available blood specimen, or specimen that does not meet testing requirements.\n\nFor newly enrolled patients:\n\n1. Presence of serious comorbid conditions with life expectancy ≤ 6 months.\n2. Conditions that significantly affect study compliance or the ability to complete follow-up.\n3. Contraindications to blood sampling.",{"count":345,"type":20},12154,"Patients with coronary heart disease who take dual antiplatelet therapy face two serious risks: thrombosis and major bleeding. This study aims to develop better ways to predict these risks and guide personalized treatment.\n\nThe investigators will use a large, long-term follow-up study of Chinese patients with coronary heart disease. This research plans to discover new biomarkers related to clot and bleeding risk. The study will combine information from proteins, metabolites, sugars attached to proteins, genes, and medical images. Using machine learning methods, the investigators will identify the most important markers and test them in the patient group of this study.\n\nThe investigators will then build new risk prediction models that include these new markers together with traditional risk scores (such as GRACE, PARIS, and Precise-DAPT). This study will check whether these new models are better than existing ones at predicting who will develop clots or bleeding and at helping doctors decide on the best treatment for each patient.\n\nThe new aspects of this research are: (1) using advanced multi-omics technology to find novel markers specifically for Chinese patients; (2) combining clinical, biological, and imaging data to improve prediction accuracy; and (3) using machine learning to create more precise risk models.\n\nThe goal is to provide doctors with a more accurate tool to assess each patient's risk of clots and bleeding. This will help them choose the safest and most effective antiplatelet treatment, reduce serious complications, and improve patient care.",[28,176,348],"Coronary Artery Disease (CAD)",[350,351,28,176,352,353,354,355],"Coronary Heart Disease","Dual Antiplatelet Therapy","Multi-Omics","Biomarkers","Risk Prediction Model","Machine Learning","2026-04-06",{"date":358,"type":41},"2026-04-13",{"date":360,"type":41},"2025-08-01",{"date":362,"type":20},"2029-07",{"name":364,"class":76},"Xueyan Zhao",{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":142,"sex":17,"minAge":372,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":61,"phases":376,"briefSummary":377,"conditions":378,"keywords":385,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":398},"100568106","neonatal-platelet-transfusion-threshold-trial-100568106","NCT06676904","Neonatal Platelet Transfusion Threshold Trial","NeoPlaTT","Inclusion Criteria:\n\n* Gestational age of 23 0\u002F7 to 26 6\u002F7 weeks\n* Postnatal age of \\\u003C 48 hours\n\nExclusion Criteria:\n\n* Comfort care or withdrawal of care planned\n* Neonatal alloimmune thrombocytopenia or suspected\u002Fconfirmed congenital platelet or bleeding disorder\n* Receipt of platelet transfusion\n* No receipt of Vitamin K\n* Parents\u002Fguardian decline consent","1 Hour","48 Hours",{"count":375,"type":20},2433,[206],"The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0\u002F7 to 26 6\u002F7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0\u002F7 weeks' postmenstrual age (PMA).",[379,380,381,382,383,384,28],"Thrombocytopenia","Neonatal","Platelet Transfusion","Infant, Newborn, Diseases","Infant, Extremely Low Birth Weight","Infant, Small for Gestational Age",[386,387,388],"platelet transfusion","neonatal","thrombosis","2026-03-24",{"date":391,"type":41},"2026-03-25",{"date":393,"type":41},"2025-06-13",{"date":395,"type":20},"2031-04-30",{"name":397,"class":48},"NICHD Neonatal Research Network",20,{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":61,"phases":408,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":110},"100631272","phase-2-safety-and-efficacy-of-a-single-dose-of-gruticibart-to-prevent-crt-100631272","NCT07498517","Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT","A Study to Evaluate the Safety and Efficacy of a Single Dose of Gruticibart for the Prevention of Early Catheter-related Thrombosis","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document.\n* Men and women, aged ≥ 18 years.\n* In consultation with PI and treating physician, participant's therapy allows for a 1 to 2-day period between administration of study drug and subsequent start of planned therapy.\n* Individuals that will undergo insertion of a CVC as part of planned therapy per institutional standards.\n* Must have ECOG performance status ≤ 2 (refer to Appendix A).\n* At time of enrollment, must have:\n\n  * Platelet count \\> 50 x 109\u002FL\n* Female participants of childbearing potential must have a negative urine or serum pregnancy test during screening and at check-in Day -1. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Participants of childbearing potential are defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not postmenopausal.\n* Female participants of childbearing potential must agree to use two forms of highly effective contraception (Appendix B) starting with the first dose of study therapy through 90 days after the last dose of study therapy.\n\nParticipants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\>1 year without an alternative medical cause.\n\n* Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy.\n\nExclusion Criteria:\n\n* Concurrent enrollment in another therapeutic clinical trial\n* Active leukemia (lymphoma and myeloma may be included)\n* Primary brain tumors or known brain metastases\n* Active infection and\u002For current use of an oral antibiotic\n* At time of enrollment:\n\n  * Deranged baseline clotting, where INR \\> 1.5\n  * Known bleeding diathesis\n  * Use of anticoagulation, either therapeutic or prophylactic, for any indication at enrollment\n* -At the discretion of the investigator, any other contraindication to anticoagulation therapy\n* Previously documented hypersensitivity to either the drug or excipients.\n* Psychiatric illness\u002Fsocial situations, or any other condition, that in the opinion of the investigator, would limit compliance with study requirements.\n* Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 90 days after study drug administration.",{"count":407,"type":20},90,[409],"PHASE2","This phase II trial studies how well gruticibart works in reducing the incidence of catheter-related thrombosis (CRT) blood clots in patients with a central venous catheter (CVC) inserted. Many patients develop blood clots from their catheters and can have pain, swelling, and other symptoms. They also often require blood thinners, which can increase the risk of bleeding. Gruticibart, a type of drug called a monoclonal antibody, may prevent blood clots caused by a catheter.",[28],"2026-03-23",{"date":414,"type":41},"2026-03-27",{"date":416,"type":20},"2026-02-28",{"date":418,"type":20},"2029-10-02",{"name":420,"class":76},"OHSU Knight Cancer Institute",{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":110},"100524805","non-invasive-coronary-thrombus-imaging-to-define-these-cause-of-acute-myocardial-infarction-100524805","NCT06113510","Non-invasive Coronary Thrombus Imaging to Define These Cause of Acute Myocardial Infarction","Non-invasive Coronary Thrombus Imaging to Define the Cause of Acute Myocardial Infarction","Inclusion Criteria:\n\n* Males and females ≥ 18 years of age\n* Clinical presentation of chest pain, ST-segment deviation within a coronary artery territory on the electrocardiogram, raised cardiac troponin and non-obstructive coronary arteries on invasive coronary angiography as per international societal diagnostic criteria\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* Takatsubo cardiomyopathy\n* Myocarditis\n* Renal failure (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m2)\n* Woman of child-bearing potential who are pregnant or breastfeeding\n* Known allergy or contraindication to iodinated contrast or radiotracer\n* Patients unable to tolerate the supine position\n* Patients unable to provide informed consent",{"count":429,"type":20},80,"We now have very sensitive blood tests that can pick up damage to the heart and find patients who have had a heart attack. However, whilst this is welcome, it does not identify what causes the heart attack and can sometimes pick up other conditions that cause a strain on the heart.\n\nThe classic cause of a heart attack is when a blood clot forms on fatty deposits within the heart arteries. This leads to treating patients with blood thinning medication, and this is very effective and saves lives. However, many apparent heart attacks are not caused by blood clots and some may be caused by blood clots but pass unrecognised.\n\nIn this proposal, we will test an exciting new imaging test that can 'see' from outside the body whether there is a blood clot in the heart arteries. This could provide a major new way of assessing patients to ensure they get the right diagnosis and the right treatment. This could ultimately improve the outcomes of or patients with heart attacks.\n\nWe will recruit 80 patients in total who have recently been diagnosed with a heart attack from the cardiology department at the Royal Infirmary of Edinburgh. The research team will review patient's medical records to determine eligibility for the study.\n\nThe research study involves participants undertaking the following research procedures and assessments:\n\n1. A combined Positron Emission Tomography and Computed Tomography (PET-CT) scan of the heart\n2. Ultrasound scan of the heart (Echocardiogram)\n3. MRI scan of the heart\n4. A blood test - a total of up to four tablespoons (60 mL) of blood will be taken for immediate testing and the remaining blood will be stored for future ethically approved studies\n5. A follow up questionnaire 6 -12 months following the heart attack",[432,28],"Myocardial Infarction","2026-03-13",{"date":435,"type":41},"2026-03-17",{"date":437,"type":41},"2025-01-06",{"date":439,"type":20},"2028-04-01",{"name":441,"class":76},"University of Edinburgh",{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":142,"sex":17,"minAge":86,"maxAge":449,"enrollmentInfo":450,"targetDuration":4,"studyType":61,"phases":452,"briefSummary":454,"conditions":455,"keywords":459,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":110},"100349477","phase-1-positron-emission-tomography-pet-imaging-of-thrombosis-100349477","NCT03830320","Positron Emission Tomography (PET) Imaging of Thrombosis","Preliminary Evaluation of [64Cu]FBP8 in Healthy Individuals and Subjects With Known or at Risk of Developing Thrombosis","For Atrial Fibrillation Patient subjects:\n\n* History of atrial fibrillation or paroxysmal atrial fibrillation;\n* Retrospective enrollment: TEE to evaluate LAA within the last 14 days, provided the anticoagulation regimen the patient is on is not changed after the TEE. If a patient has a negative TEE and continues the same stable anti-coagulation regimen he\u002Fshe is on, then it is extremely unlikely that a new thrombus will develop in the left atrial appendage within the next two weeks. Likewise, if a patient not taking any anti-coagulation has a thrombus in the left atrial appendage, then it is extremely unlikely that this thrombus will resolve spontaneously in the next 14 days if the patient continues not to take any anticoagulation. If the TEE leads to a change being made in the anticoagulation regimen (started\u002Fstopped\u002Fdose modified), then a time window of 72 hours from the TEE to PET imaging will be used. This scheme will ensure that the TEE can serve as an accurate gold standard;\n* Prospective enrollment: TEE to evaluate LAA scheduled in upcoming 14 days;\n\nFor COVID-19 Patient subjects:\n\n* Positive test for SARS-CoV-2 RNA detected by RT-PCR collected from the upper or lower respiratory tract analyzed by a certified lab with an FDA approved assay within the last month;\n* Patient not requiring mechanical ventilation;\n\nFor Cancer Patient subjects:\n\n• Patient is diagnosed with cancer;\n\nFor Other Patient subjects:\n\n* Ultrasound- or CT-confirmed or high likelihood of thrombus (e.g., elevated D-dimer)\n* Has not received thrombolytics\n\nExclusion criteria: A subject will not be eligible for inclusion in this study if any of the following criteria apply:\n\n* Subjects less than 18 years of age;\n* Electrical implants such as cardiac pacemaker or perfusion pump;\n* Pregnant or breastfeeding (a negative STAT quantitative serum hCG pregnancy test is required for females having child-bearing potential before the subject can participate);\n* Claustrophobic reactions;\n* Subjects will be excluded if research-related radiation exposure exceeds current Radiology Department guidelines (i.e. 50 mSv in the prior 12 months);\n* Unable to lie comfortably on a bed inside the PET scanner;\n* Subjects under direct or indirect (i.e. same department as PIs) supervision of the principal investigator;\n* Body weight over the weight limit for the moving table (\\> 300 lbs for the MRI table and \\>441 lbs for the CT table);\n* Metallic or electric implants contraindicated for MR-PET scanning when applicable;\n* Does not have the ability to give written informed consent.\n* Determined by the investigator(s) to be clinically unsuitable for the study (e.g. based on screening visit and\u002For during study procedures);\n\nAdditional exclusion criteria for Atrial Fibrillation Patient subjects:\n\n* Stroke within the last 3 months;\n* Myocardial infarction within the last 3 months;\n* Cardiac or major surgery within the last 3 months;\n* History of chest pain within the last 6 weeks unless followed by a subsequent stress test or coronary angiography;\n* History of syncope within the last 6 weeks;\n* Heart rate persistently \\>120 bpm or persistently \\\u003C 50 bpm;\n* Presence of daytime pauses \\> 3s","85 Years",{"count":451,"type":20},165,[453],"PHASE1","The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasive alternative to the current standard-of-care methods.",[456,457,458,28],"Atrial Fibrillation","COVID-19","Cancer",[460],"PET-MRI","2026-02-25",{"date":463,"type":41},"2026-02-27",{"date":465,"type":41},"2016-04-01",{"date":467,"type":20},"2027-01-31",{"name":230,"class":76},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":17,"minAge":145,"maxAge":476,"enrollmentInfo":477,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":110},"100549452","extracellular-vesicle-micro-rna-profiling-in-congenital-heart-disease-fetal-maternal-regulation-in-neonatal-thrombosis-100549452","NCT06434207","Extracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis","EVmiRNA","Inclusion Criteria:\n\n* All neonates with a diagnosis of severe Congenital Heart Disease undergoing surgery at Boston Children's Hospital in the first week of life\n\nExclusion Criteria:\n\n* None","7 Days",{"count":478,"type":20},10,"Newborns with congenital heart disease (CHD) are at increased risk of developing postpartum and postoperative blood clots after cardiac surgery. The molecular mechanisms that are responsible for the clotting profile predisposing children to blood clots in the early stages of life are currently not well described.\n\nThe goal of this proposal is to prospectively collect plasma samples from ten (10) neonates with antenatal diagnosis of severe congenital heart disease (CHD) to better understand mechanisms responsible for abnormal clotting in the perioperative period.",[481,482,28],"Congenital Heart Disease","Single-ventricle","2026-02-20",{"date":485,"type":41},"2026-02-23",{"date":487,"type":41},"2024-10-31",{"date":489,"type":20},"2026-12-01",{"name":491,"class":76},"Boston Children's Hospital",{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":500,"targetDuration":4,"studyType":61,"phases":502,"briefSummary":503,"conditions":504,"keywords":505,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":516},"100545761","thrombin-generation-parameters-and-bleeding-in-patients-treated-with-anticoagulants-for-cancer-associated-thrombosis-100545761","NCT06386107","Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis","Association Between Thrombin Generation Parameters and the Risk of Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis (CAT) (a Multicenter Study)","CATforCAT","Inclusion Criteria:\n\n* Patients with active cancer, as defined by current French recommendations (Mahé I et al Rev Mal Respir 2021)\n* Presenting acute proximal deep vein thrombosis of the lower limb (DVT) and\u002For proximal pulmonary embolism (at least segmental) (PE), confirmed by objective tests (Doppler ultrasound in the event of DVT; lung scintigraphy or CT scan in the event of PE)\n* No contraindication for anticoagulant treatment at a curative dose at the time of inclusion\n\nExclusion Criteria:\n\n* Patients participating in a therapeutic clinical trial with a blinded therapy or an open-label therapeutic trial who are included in the experimental treatment group.\n* Patients already on anticoagulant at a curative dose for valvular or rhythmic embolic disease or a history of venous thromboembolic disease\n* Hematological malignancies\n* Patients with a contraindication to anticoagulant treatment on inclusion\n* Patient whose relay by DOAC has already been carried out.",{"count":501,"type":20},212,[206],"Pulmonary embolism, the second leading cause of death in cancer patients, is effectively treated with anticoagulants. In patients with cancer-associated thrombosis (CAT), the use of anticoagulants is associated with 10 to 15% of bleeding in the first 6 months. Most of the guidelines propose to integrate the bleeding risk in the choice of therapies. Thrombin generation assay (TGA) reflects an overall hemostatic response and could be a useful biomarker. Proven on the thrombotic side in the CAT population, useful in the assessment of the bleeding risk of hemophiliac patients, the TGA is emerging as a tool. The investigators to measure TGA in cancer patients included prospectively, having recently developed a CAT and to evaluate the association between the measurement and the risk of hemorrhagic complication under anticoagulant during the first 6 month of treatment.",[458,123,28],[458,28,506],"Anticoagulant associated bleeding","2026-02-11",{"date":509,"type":41},"2026-02-12",{"date":511,"type":41},"2025-09-02",{"date":513,"type":20},"2028-07",{"name":515,"class":76},"Centre Hospitalier Universitaire de Saint Etienne",4,{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":61,"phases":527,"briefSummary":528,"conditions":529,"keywords":533,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":4},"100621599","safety-of-perioperative-anticoagulation-management-in-people-with-active-cancer-undergoing-cancer-related-surgery-or-procedures-ace-high-study-100621599","NCT07372716","Safety of Perioperative Anticoagulation Management in People With Active Cancer Undergoing Cancer-Related Surgery or Procedures (ACE-HIGH Study)","Active Cancer Patients Having Cancer Related Invasive Procedures or Surgery and Needing Perioperative Management of Anticoagulation Therapy (ACE-HIGH): A Prospective Management Cohort Study","ACE-HIGH","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Prescribed a Direct Oral Anticoagulant (DOAC), warfarin (International Normalized Ratio (INR) target 2.0-3.0) or Low Molecular Weight Heparin (LMWH) (75-100% weight-based therapeutic dosing) for stroke prevention in Atrial Fibrillation (AF) or the treatment of Venous Thromboembolism (VTE). Eligible DOAC regimens include full-dose (therapeutic) DOAC regimens appropriate for age and renal function. Eligible DOAC regimens include:\n\n  i. Apixaban 10 mg po BID (VTE) ii. Apixaban 5 mg po BID (AF or VTE) iii. Apixaban 2.5 mg po BID (AF) iv. Rivaroxaban 15 mg po BID (VTE) v. Rivaroxaban 20 mg po OD (AF or VTE) vi. Rivaroxaban 15 mg po OD (AF only) vii. Edoxaban 60 mg po OD (AF or VTE) viii. Edoxaban 30 mg po OD (AF or VTE) ix. Dabigatran 150 mg po BID (AF or VTE) x. Dabigatran 110 mg po BID (AF)\n* Has active cancer, defined as:\n\n  i. cancer diagnosed within 6 months ii. recurrent, regionally advanced, or metastatic cancer iii. cancer for which treatment had been administered within 6 months before enrolment iv. hematologic cancer that is not in remission v. Patients who are felt to likely have active cancer based on clinical\u002Fimaging characteristics but are awaiting tissue confirmation and are scheduled for a biopsy procedure are eligible for trial inclusion\n* Is undergoing a planned cancer-related inpatient or outpatient invasive procedure or cancer surgery (to diagnose, treat or palliate cancer; at investigator's discretion)\n* Interruption of anticoagulation therapy for the planned procedure is required.\n\nExclusion Criteria:\n\n* Presence of any mechanical prosthetic heart valve\n* Known pregnancy or breastfeeding\n* Severe renal insufficiency (Creatinine Clearance (CrCl) \\\u003C 30 mL\u002Fmin or \\\u003C 25 mL\u002Fmin for Apixaban users)\n* Condition that might impair adherence to the study protocol (e.g., cognitive impairment, geographic inaccessibility) as determined by the treating physician\n* Allergy to heparin or a history of (Heparin Induced Thrombocytopenia (HIT)\n* More than one surgery\u002Fprocedure planned during the study period\n* Previous study participation\n* Inability to provide informed consent",{"count":526,"type":20},700,[206],"The purpose of this study is to help find how safe current practices are when managing blood thinners in people with cancer who are having surgery or medical procedures. Investigators will also measure how often bleeding or clotting problems happen in this setting. The goal is to use this information to improve future care and reduce these risks for patients. This study will determine whether contemporary practices can be safely applied to cancer patients, and also evaluate the blood thinner level left over in patient's body at the time of surgery.",[28,458,530,531,532,176],"Thrombosis, Deep Vein","Atrial Fibrillation (AF)","Venous Thromboembolic Event",[388,534,458,535,536,537],"Atrial fibrillation","Anticoagulant Interruption","VTE","bleeding","2026-02-05",{"date":540,"type":41},"2026-02-06",{"date":542,"type":20},"2026-03",{"date":544,"type":20},"2031-12",{"name":546,"class":76},"Ottawa Hospital Research Institute",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":554,"targetDuration":556,"studyType":21,"phases":4,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":110},"100620011","incidence-of-bleeding-thrombosis-and-transfusion-requirements-in-icu-patients-with-covid-19-supported-with-veno-venous-extracorporeal-membrane-oxygenation-100620011","NCT07352072","Incidence of Bleeding, Thrombosis and Transfusion Requirements in ICU Patients With COVID-19 Supported With Veno-venous Extracorporeal Membrane Oxygenation","Incidence of Bleeding, Thrombosis and Transfusion Requirements in ICU Patients With COVID-19 Supported With Veno-venous Extracorporeal Membrane Oxygenation: a Single-center Retrospective Cohort Study","Inclusion criteria:\n\n* Adults\n* Polymerase chain reaction (PCR) verified COVID-19 infection\n* Supported with V-V ECMO in this center\n\nExclusion criteria:\n\n\\- none",{"count":555,"type":20},50,"90 Days","The investigators aim to assess the risk of bleeding and thrombo-embolic complications as well as benefit and harm of blood product transfusion and anticoagulation therapy in adult ICU patients with COVID-19 supported with V-V ECMO",[559,176,28,560,457],"VV ECMO","Transfusion Adverse Reaction","2026-01-27",{"date":563,"type":41},"2026-01-29",{"date":565,"type":20},"2026-01",{"date":567,"type":20},"2026-12",{"name":569,"class":76},"Rigshospitalet, Denmark",{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":578,"enrollmentInfo":579,"targetDuration":4,"studyType":61,"phases":580,"briefSummary":581,"conditions":582,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":4},"100621936","effects-of-sweetener-consumption-on-risk-factors-for-heart-disease-in-prediabetic-subjects-100621936","NCT07377097","Effects of Sweetener Consumption on Risk Factors for Heart Disease in Prediabetic Subjects","Effects of Sweetener Consumption on Risk Factors for Heart Disease","Sweetheart","Inclusion Criteria:\n\n* Presence of prediabetes (HbA1c 5.7-6.4% or glucose after oral glucose tolerance test 140 to 199 mg\u002FdL)\n* Written informed consent available\n\nExclusion Criteria:\n\n* Inability to communicate sufficiently in the required language\n* Dementia or other significantly cognitively impairing condition\n* Current pregnancy or breastfeeding\n* Other severe internal, neurological, or psychiatric condition\n* History of gout\n* History of gallstones \u002F diagnosis of cholelithiasis","75 Years",{"count":429,"type":20},[206],"The aim of this prospective interventional study is to investigate the metabolic effects of consuming artificial and natural sweeteners in persons with prediabetes. Prediabetes is a condition characterized by blood sugar levels that are elevated above normal but not yet meeting the criteria for type 2 diabetes. This condition markedly increases the risk of progressing to type 2 diabetes, which in turn can lead to complications including cardiovascular diseases.\n\nArtificial sweeteners such as saccharin and sucralose, as well as natural sugar substitutes like erythritol, are increasingly used as alternatives to sugar and are recommended for individuals at cardiometabolic risk - including overweight individuals, patients with prediabetes, or diabetics - to help reduce caloric intake. Recent literature has reported possible negative associations between artificial sweeteners and blood sugar regulation in healthy subjects (1). Additionally, effects on various blood cells have been observed. For example, erythritol has been shown to alter platelet function leading to increased reactivity in healthy study participants following consumption (2).\n\nHowever, the impact of alternative sweeteners on metabolic processes and their effects on blood coagulation in patients with prediabetes-a population at increased risk-has not been systematically studied. In this planned interventional study, 80 patients meeting laboratory criteria for prediabetes will be randomly assigned to one of four groups, each receiving a different intervention for two weeks: saccharin, sucralose, erythritol, or a control group receiving water. The doses reflect the acceptable daily intake or known doses that are considered safe.\n\nAfter enrollment, participants will visit the study center 2 times: before starting the intervention and after completing the intervention. During these visits, biological samples such as blood, urine, and stool will be collected to study metabolism, gut bacteria, immune and blood cell function. Tests will include an oral glucose tolerance test, coagulation tests, and additional blood analyses. Additionally, participants will wear a glucose monitor to track blood sugar fluctuations during the intervention.\n\nThe investigators hypothesize that consumption of alternative sweeteners negatively affects blood sugar regulation and insulin sensitivity in patients with prediabetes. Furthermore, this study will explore how the candidate sweeteners influence the gut microbiome, blood cells and other metabolic factors in this population.",[583,584,585,28,586,587,588,589,590,591,592],"Prediabetic State","Metabolic Syndrome","Insulin Resistance","Hypercoagulable State","Cardiovascular (CV) Risk","Cardiovascular Risk Factors","Cardiovascular Diseases (CVD)","Prediabetes","Prediabetes \u002F Type 2 Diabetes","Sweeteners","2026-01-22",{"date":563,"type":41},{"date":596,"type":20},"2026-01-05",{"date":598,"type":20},"2026-11-01",{"name":600,"class":76},"Charite University, Berlin, Germany",{"id":602,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":604,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":609,"leadSponsor":610,"locationsCount":49},"100393100",{"count":19,"type":20},[24,25,26,27,28,29,30,31,32,33,34,35,36],"2026-01-09",{"date":607,"type":41},"2026-01-12",{"date":43,"type":41},{"date":45,"type":20},{"name":47,"class":48},{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":620,"conditions":621,"keywords":636,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":110},"100616152","generative-ai-impact-on-rheumatoid-arthritis-complications-diagnosis-100616152","NCT07301892","Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis","Impact of Generative Artificial Intelligence on Diagnosing Rheumatoid Arthritis Complications","Inclusion Criteria:\n\n* Patients with an initial diagnosis of rheumatoid arthritis (RA).\n* All real-world RA inpatients admitted to our department.\n* Admission occurring within the real-world data study period.\n\nExclusion Criteria:\n\n* Patients subsequently confirmed not to have RA during the study.",{"count":619,"type":20},100,"Generative AI (GenAI) based on large language models (LLMs) is expected to improve the diagnosis and treatment of autoimmune diseases. We are studying how GenAI may affect the diagnosis of various complications of rheumatoid arthritis (RA). In a retrospective study using RA patients' EHR records, we will quantify physician adoption of GenAI predictions for RA complications and co-existing diseases. In a prospective observational study, we will assess the feasibility of using GenAI predictions as additional clinical information to help physicians make more complete diagnoses of RA complications and co-existing diseases, including complex, uncommon, or rare conditions.",[622,623,624,625,626,627,628,629,630,631,632,633,634,28,635],"Rheumatoid Arthritis (RA","Osteoporosis","Osteoarthritis","Interstitial Lung Disease","Thyroid Diseases","Cardiovascular Diseases","Pulmonary Complications","Sjogren's Syndrome","Liver Disorders","Renal Lesions","Vasculitis","Amyloidosis","Peripheral Neuropathy","RA Complications",[637,638,639,640],"Rheumatoid Arthritis","generative AI","large language model","Rheumatoid arthritis complications","2025-12-22",{"date":643,"type":41},"2025-12-24",{"date":645,"type":41},"2025-10-01",{"date":647,"type":20},"2026-06",{"name":649,"class":76},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":4,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":657,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":658,"conditions":659,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":674,"startDateStruct":676,"completionDateStruct":678,"leadSponsor":680,"locationsCount":110},"100487581","vascular-lab-resource-vlr-biorepository-100487581","NCT05628948","Vascular Lab Resource (VLR) Biorepository","Vascular Lab Resource (VLR) Biorepository Study","Inclusion Criteria:\n\n1. 18 years or older\n2. Subjects capable of providing informed consent document\n3. Subjects with diagnosed with or at risk for cardiovascular and metabolic diseases\n\nExclusion Criteria:\n\n1. Known life expectancy of ≤ 6 months at the time of enrollment\n2. Known current pregnancy\n3. Severe Anemia (last documented hemoglobin \\\u003C 7.0 g\u002FdL)",{"count":144,"type":20},"This is a study of biomarkers obtained from prospectively collected subject samples and their correlation with cardiovascular and metabolic diseases. The purpose of this initiative is to develop an enduring tool to allow for collaborative research between clinicians at Cleveland Clinic Main Campus and basic scientists at the Lerner Research Institute. This collaboration will allow resources to be available to clinical and basic researchers alike. This tool will enable research of vascular disease in the Vascular Lab and will leverage this valuable asset to the fullest extent to allow for interdepartmental collaboration.",[627,660,661,662,663,664,28,665,666,667,632,668,669,670,671,672],"Metabolic Disease","Peripheral Artery Disease","Carotid Disease","Aneurysmal Disease","Venous Disease","Lymphedema","Lipedema","Non-Atherosclerotic Chronic Arterial Occlusive Disease","Fibromuscular Dysplasia","Arterial Dissection","May-Thurner Syndrome","Thoracic Outlet Syndrome","Vasospasm","2025-12-15",{"date":675,"type":41},"2025-12-19",{"date":677,"type":41},"2019-11-14",{"date":679,"type":20},"2031-06-30",{"name":681,"class":76},"The Cleveland Clinic",{"id":683,"slug":684,"hasResults":12,"nctId":685,"briefTitle":686,"officialTitle":686,"acronym":687,"eligibilityCriteria":688,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":689,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":691,"conditions":692,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":694,"lastUpdatePostDateStruct":695,"startDateStruct":697,"completionDateStruct":699,"leadSponsor":701,"locationsCount":110},"100488179","the-origin-and-role-of-thromboembolism-in-the-pathogenesis-of-ischaemic-stroke-100488179","NCT05636748","The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke","TORPIS","Inclusion Criteria:\n\n* Males and females ≥18 years old\n* Diagnoses of acute ischaemic stroke (within 21 days of symptom onset) as per American Heart and Stroke Association guidelines\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide informed written consent (ie lack capacity)\n* Inability to undergo the scanning protocol including ability to transfer onto the scanner\n* Women of child- bearing potential in whom pregnancy cannot be excluded\n* Contraindication to PET-CT scanning including estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m2\n* Participation in the study would result in a delay to carotid endarterectomy surgery\n* Known allergy to iodinated contrast or radiotracer\n* Severe or significant comorbidity precluding ability to complete study procedures.\n* Haemorrhagic stroke\n* Contra-indication to Magnetic Resonance imaging for those patients requiring a MRI Head",{"count":690,"type":20},120,"Ischaemic stroke is usually due to occlusion of a cerebral artery by thrombus. However, it is often difficult to identify the source of thrombus, or to confirm thrombus as a cause of ischaemic stroke. Moreover, it is debated whether thrombosis plays any role in certain types of stroke such as lacunar stroke. In preliminary studies, the investigators have evaluated a novel clinical grade thrombus-specific radiotracer, 18F-GP1, which has a high specificity for the glycoprotein IIb\u002FIIIa receptor on activated platelets. The investigations have demonstrated that 18F-GP1 is highly sensitive to in vivo thrombus formation and demonstrates avid binding to thrombus associated with myocardial infarction, pulmonary embolism and aortic bioprosthesis. This study will use this imaging approach to define the role and origin of thrombus in patients with ischaemic stroke, cryptogenic stroke and lacunar stroke.The investigators will also assess its added clinical value in assessing patients with ischaemic stroke.",[177,693,28],"PET","2025-12-01",{"date":696,"type":41},"2025-12-02",{"date":698,"type":41},"2023-02-28",{"date":700,"type":20},"2026-08-01",{"name":441,"class":76}]